Regentis Biomaterials cash flow statement data for the quarter ended Dec 2025. This cash flow statement covers 2 quarters of results from Dec 2024 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2024 | Dec2025 |
|---|---|---|
| Operating Activities | ||
| Share-based CompensationStock Comp. | 79,290.00 | 965,000.00 |
| Financing Activities | ||
| Change in Capital Stock | ||
| Net Shares Issued and RepurchasedNet Shares Issued | 662,004.00 |